Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
42 hedge funds and large institutions have $90.9M invested in Cidara Therapeutics in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 13 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
9% more capital invested
Capital invested by funds: $83.6M → $90.9M (+$7.28M)
0.01% more ownership
Funds ownership: 3.31% → 3.33% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
22% less funds holding
Funds holding: 54 → 42 (-12)
92% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.79M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$1.66M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.02M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$178K |
| 5 |
Squarepoint
New York
|
+$147K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$1.13M |
| 2 |
Goldman Sachs
New York
|
-$650K |
| 3 |
PA
Perceptive Advisors
New York
|
-$465K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$432K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$353K |
CDTX Hedge Fund Activity: Q3 2017 in Review
42 of the 4,021 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q3 2017, worth a combined $90.9M — up 8.7% from $83.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CDTX and 1 opened new positions — a net loss of 12 holders — while 11 trimmed existing stakes and 14 added.
The largest buyer was Vanguard Group, adding an estimated $1.79M. The largest seller was Pura Vida Investments, exiting entirely with an estimated $1.13M sold.
- 42 institutional investors held Cidara Therapeutics (CDTX) as of Q3 2017, down from 54 in Q2 2017.
- Funds reported $90.9M of Cidara Therapeutics stock for Q3 2017, up 8.7% quarter-over-quarter.
- 1 fund opened new Cidara Therapeutics positions in Q3 2017 and 13 closed out, a net change of -12 holders.
- The largest Cidara Therapeutics buyer in Q3 2017 was Vanguard Group, an estimated $1.79M added.
- The largest Cidara Therapeutics seller in Q3 2017 was Pura Vida Investments, an estimated $1.13M sold.
Based on aggregated 13F filings for Q3 2017.